Fenwick Represents New Enterprise Associates in Inversago Pharma’s Series C Financing

Fenwick represented New Enterprise Associates (NEA), a global venture capital firm, in IP diligence related to Inversago Pharma’s $70 million (USD) Series C financing. Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists. NEA led the financing round, which included new investors Forbion’s Growth Opportunities Fund and Amgen Ventures and current investors Forbion’s Ventures Fund IV, Fonds de solidarité FTQ, Genesys Capital, AmorChem, JDRF T1D Fund and adMare BioInnovations.

Proceeds from the Series C financing will be used to move Inversago’s lead program, INV-202, into a Phase 2 clinical trial in Diabetic Kidney Disease in Q4 2022. More information can be obtained from the announcement.

The Fenwick team included intellectual property partner Dr. Carl Morales and patent agent Dr. Hugo Garrido.